Skip to content
Open access

Real-world effectiveness and safety of secukinumab in giant cell arteritis: an Italian multicentre cohort study.

Sep 2026 · Arthritis care & research · 0 citations
Medicine

TL;DR

In this multicentre real-world cohort of patients with GCA, including those with relapsing disease and previous biologic exposure, secukinumab was associated with high observed remission rates, progressive GC dose reduction and increasing GC-free remission.

Abstract

Objective

The objective of this study was to evaluate the real-world effectiveness and safety of secukinumab in giant cell arteritis (GCA) patients.

Methods

This multicentre retrospective study included patients with GCA who received secukinumab at 14 Italian centres with at least 6 months of follow-up. Outcomes included clinical, complete and glucocorticoid (GC)-free remission, GC dose reduction, drug retention rate and adverse events.

Results

Thirty-six patients were included (66.7% women); median age at secukinumab initiation was 74 (IQR 70-80) years. Overall, 32/36 patients (88.9%) had previously relapsed and 26/36 (72.2%) had received tocilizumab. Clinical remission was observed in 85.2%, 80.6% and 83.3% at 3, 6 and 12 months, respectively. Complete remission occurred in 55.6%, 52.8% and 63.3%, while GC-free remission increased progressively, reaching 14.8%, 27.8% and 40.0% at 3, 6, and 12 months, respectively (p = 0.012). Median daily GC dose decreased from 8.7 [4.0-21.2] mg at baseline to 0 [0-5.0] mg at 12 months (p < 0.001); GCs were discontinued in 12/28 patients (42.9%). The 12-month retention rate was 77.0%. Adverse events occurred in 20/36 patients (55.6%); infections occurred in 18/36 (50.0%) patients, accounting for 21 infectious episodes.

Conclusion

In this multicentre real-world cohort of patients with GCA, including those with relapsing disease and previous biologic exposure, secukinumab was associated with high observed remission rates, progressive GC dose reduction and increasing GC-free remission. Although the phase III GCAptAIN trial did not meet its primary endpoint, these findings suggest that IL-17A inhibition may warrant further evaluation in GCA patients.

Read PDF

Similar papers

Review Open access Oct 2026

Real-world observational study of ocrelizumab and ofatumumab in patients with multiple sclerosis in Brazil

Background: Anti-CD20 therapies are widely used in multiple sclerosis (MS), and real-world data may complement findings from clinical trials. Objective: The objective is to evaluate the effectiveness and safety of ofatumumab and ocrelizumab in patients with MS in a real-world setting. Methods: This was a single-center,...

Carolina Mibielli de Souza, Samara Abdo El Hakim Kadri, C. Disserol et al. · 0 citations
Open access Oct 2026

Real-world effectiveness and safety of Ocrelizumab in a gulf multiple sclerosis cohort: extension of the Q-OCRE study to 451 patients.

Real-world evidence on ocrelizumab in multiple sclerosis (MS) from the Middle East and North Africa (MENA) is limited. We extended our original Q-OCRE cohort (n = 60) to evaluate effectiveness and safety in an ethnically diverse Gulf population. In a single-center retrospective cohort of all patients starting ocrelizum...

Khaled Zammar, Majd A. Abualrob, Randa Yasin et al. · 0 citations
Open access Oct 2026

Serum ferritin predicts response to tocilizumab in glucocorticoid-resistant adult-onset Still's disease: a prospective real-world cohort study.

OBJECTIVES To evaluate the real-world effectiveness and safety of tocilizumab (TCZ) in glucocorticoid (GC)-resistant adult-onset Still's disease (AOSD) and explore predictors of clinical response. METHODS This prospective, single-centre cohort study enrolled consecutive eligible patients with GC-resistant AOSD who in...

Dou-Dou Ma, Hai-Hong Yao, Xia Zhang et al. · 0 citations
Open access Nov 2026

Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis

BACKGROUND Many patients with Crohn’s disease (CD) remain uncontrolled despite multiple biologic therapies. Risankizumab, a selective interleukin-23p19 inhibitor, has shown efficacy in clinical trials, but real-world data in multirefractory CD are still scarce. AIM To evaluate the 12-month effectiveness and safety o...

A. Caballero-Mateos, T. Valdés-Delgado, R. Olmedo Martín et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.